^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MB-CART20.1

    i
    Other names: MB-CART20.1, MB CART20.1, anti-CD20 CAR T cells, MBCART20.1
    Associations

    News

    Trials
    Company:
    Miltenyi Biotec
    Drug class:
    CD20-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1m
    Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma. (PubMed, Front Immunol)
    In conclusion, the CliniMACS Prodigy® platform is well suited for decentralized POC manufacturing of anti-CD20 CAR T cells and may be likewise applicable for the rapid and automated manufacturing of CAR T cells directed against other targets. https://clinicaltrials.gov/study/NCT03893019?cond=Melanoma&term=NCT03893019&rank=1, identifier NCT03893019.
    Journal • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    MB-CART20.1
    4ms
    LONGSAFE: Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Miltenyi Biomedicine GmbH
    New trial • Gene therapy
    |
    MB-CART 19.1 • MB-CART20.1 • zamtocabtagene autoleucel (MB-CART2019.1)
    6ms
    MB-CART20.1 Melanoma (clinicaltrials.gov)
    P1, N=9, Terminated, Miltenyi Biomedicine GmbH | N=15 --> 9 | Recruiting --> Terminated; The risk-benefit assessment was not as expected.
    Enrollment change • Trial termination • Metastases
    |
    MB-CART20.1
    7ms
    MB-CART20.1 Lymphoma (clinicaltrials.gov)
    P1/2, N=19, Active, not recruiting, Miltenyi Biomedicine GmbH | Trial completion date: Nov 2022 --> Sep 2024 | Trial primary completion date: Feb 2022 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    MB-CART20.1
    almost2years
    A Phase I Dose Finding Trial of MB-CART20.1 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (ASH 2022)
    Patients underwent lymphodepletion with fludarabine (30 mg/m2) and cyclophosphamide (300 mg/m2), each from day -5 to day -3...One CRS case was managed with tocilizumab...In total 3 patients achieved a CR and remained in remission for at least one year. The two patients treated at the higher DL, achieved a CR indicating a dose-response correlation.
    Clinical • P1 data
    |
    CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab) • MB-CART20.1
    3years
    MB-CART20.1 Melanoma (clinicaltrials.gov)
    P1, N=15, Recruiting, Miltenyi Biomedicine GmbH | Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    MB-CART20.1
    3years
    MB-CART20.1 Lymphoma (clinicaltrials.gov)
    P1/2, N=19, Active, not recruiting, Miltenyi Biomedicine GmbH | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    MB-CART20.1